ATE286067T1 - Hcv hüllproteine partikel : verwendung für therapeutische impfung - Google Patents

Hcv hüllproteine partikel : verwendung für therapeutische impfung

Info

Publication number
ATE286067T1
ATE286067T1 AT99929306T AT99929306T ATE286067T1 AT E286067 T1 ATE286067 T1 AT E286067T1 AT 99929306 T AT99929306 T AT 99929306T AT 99929306 T AT99929306 T AT 99929306T AT E286067 T1 ATE286067 T1 AT E286067T1
Authority
AT
Austria
Prior art keywords
hcv
envelope proteins
hcv envelope
therapeutic vaccination
proteins
Prior art date
Application number
AT99929306T
Other languages
English (en)
Inventor
Erik Depla
Geert Maertens
Alfons Bosman
Wijnendaele Frans Van
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26152268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE286067(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Application granted granted Critical
Publication of ATE286067T1 publication Critical patent/ATE286067T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99929306T 1998-06-24 1999-06-23 Hcv hüllproteine partikel : verwendung für therapeutische impfung ATE286067T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98870142 1998-06-24
EP99870033 1999-02-22
PCT/EP1999/004342 WO1999067285A1 (en) 1998-06-24 1999-06-23 Particles of hcv envelope proteins: use for vaccination

Publications (1)

Publication Number Publication Date
ATE286067T1 true ATE286067T1 (de) 2005-01-15

Family

ID=26152268

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99929306T ATE286067T1 (de) 1998-06-24 1999-06-23 Hcv hüllproteine partikel : verwendung für therapeutische impfung

Country Status (20)

Country Link
US (3) US6635257B1 (de)
EP (2) EP1090033B2 (de)
JP (1) JP2002518037A (de)
KR (1) KR100559096B1 (de)
CN (1) CN1313864A (de)
AT (1) ATE286067T1 (de)
AU (1) AU765940B2 (de)
BR (1) BR9911397A (de)
CA (1) CA2330526A1 (de)
DE (1) DE69922958T3 (de)
DK (1) DK1090033T4 (de)
ES (1) ES2237115T5 (de)
HU (1) HU227275B1 (de)
IL (2) IL140217A0 (de)
NZ (2) NZ528952A (de)
PL (1) PL201679B1 (de)
PT (1) PT1090033E (de)
RU (1) RU2247729C2 (de)
TR (1) TR200003843T2 (de)
WO (1) WO1999067285A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185061A1 (en) * 1994-07-29 2004-09-23 Innogenetics N.V. Redox reversible HCV proteins with native-like conformation
EP1090033B2 (de) * 1998-06-24 2007-12-19 Innogenetics N.V. Hcv hüllproteine partikel : verwendung für therapeutische impfung
US7108855B2 (en) 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
EP1221968B1 (de) * 1999-10-13 2010-01-13 Novartis Vaccines and Diagnostics, Inc. Verfahren zur erhaltung zellimmuneantworten gegen proteinen
WO2001093905A1 (en) 2000-06-08 2001-12-13 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Immunostimulatory oligodeoxynucleotides
ATE500838T1 (de) * 2000-09-08 2011-03-15 Amylin Pharmaceuticals Inc ßPSEUDOß-NATIVE CHEMISCHE LIGATION
EP1326625A4 (de) * 2000-09-13 2005-05-04 Hawaii Biotech Inc Immunogene zusammensetzung von hepatitis c und methoden für ihre verwendung
US7101561B2 (en) * 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
JP4261195B2 (ja) * 2001-04-24 2009-04-30 イノジェネティックス・ナムローゼ・フェンノートシャップ 酵母のコア−グリコシル化されたｈｃｖエンベロープタンパク質の発現
GB0114629D0 (en) * 2001-06-15 2001-08-08 Pfizer Ltd Method
US20040126395A1 (en) * 2001-12-18 2004-07-01 Geert Maertens Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
CN1622828A (zh) * 2001-12-18 2005-06-01 基因创新有限公司 用于诊断和治疗用途的纯化的丙型肝炎病毒外被蛋白
FR2839722A1 (fr) * 2002-05-17 2003-11-21 Bio Merieux Nouvelles compositions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
JP2004085528A (ja) * 2002-07-05 2004-03-18 Kansai Tlo Kk 拡散定数変化による蛋白質の会合検出方法及び装置
WO2004028551A1 (en) * 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
EP1852441B1 (de) * 2002-09-24 2012-03-28 The Burnham Institute Mittel zur Modulierung der EPH-Rezeptor-Aktivität
EP1481985A1 (de) * 2003-05-28 2004-12-01 Innogenetics N.V. Modifiziertes Hepatitis C Virus (HCV) NS3 Protein zur medizinischen Behandlung
EP1561470A1 (de) * 2003-06-20 2005-08-10 Innogenetics N.V. HCV Vakzine beinhaltend das Hüllprotein E1 oder die korrespondierende DNA und mindestens ein antivirales Medikament
SG146662A1 (en) * 2003-10-10 2008-10-30 Powderject Vaccines Inc Method
WO2006070028A1 (es) * 2004-12-23 2006-07-06 Berthet Francois Xavier Composiciones y procedimientos para detectar infección patógena
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
EP1574517A1 (de) * 2004-03-09 2005-09-14 Innogenetics N.V. HCV E1 beinhaltend spezifische Disulfidbrücken
WO2006033012A2 (en) * 2004-09-24 2006-03-30 Pfizer Limited Method of screening for modulators of hepatitis c virus infection
DE102004057111A1 (de) 2004-11-26 2006-06-01 Niles-Simmons Industrieanlagen Gmbh Verfahren zum Zwischenbearbeiten von Wellen
EP1841790B1 (de) 2005-01-27 2010-11-03 The Burnham Institute Ephb-rezeptorbindende peptide
WO2007041432A2 (en) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Cross-neutralization of hcv with recombinant proteins
WO2007111965A2 (en) * 2006-03-22 2007-10-04 Genimmune N.V. Hepatitis c virus neutralizing antibodies
RU2329303C2 (ru) * 2006-08-02 2008-07-20 Государственное учреждение Научно-исследовательский институт вирусологии им. Д.И. Ивановского Российской академии медицинских наук Моноклональное антитело, иммунореактивное с белком нуклеокапсида (кор) вируса гепатита с-4g5, способ диагностики вгс-инфекции и комбинация моноклональных антител для его осуществления
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
CA2722423A1 (en) * 2008-04-22 2009-10-29 Rutgers, The State University Hcv e2 construct compositions and methods
CA2741961A1 (en) * 2008-11-05 2010-05-14 Glaxosmithkline Biologicals S.A. Novel method
BR112013032675A2 (pt) * 2011-06-19 2017-08-08 Vaxine Pty Ltd composição adjuvante de vacina compreendendo partículas de inulina
JP6567824B2 (ja) * 2011-10-12 2019-08-28 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
RU2510998C2 (ru) * 2012-08-01 2014-04-10 Николай Николаевич Грановский ВАКЦИНА НА ОСНОВЕ ВИРУСОПОДОБНЫХ ЧАСТИЦ, СОДЕРЖАЩИХ ВСЕ СТРУКТУРНЫЕ АНТИГЕНЫ ВИРУСА ГЕПАТИТА С, И СПОСОБ ЕЕ ПОЛУЧЕНИЯ В ДРОЖЖАХ Hansenula polymorpha
AU2014248535B2 (en) 2013-03-12 2017-03-30 Inovio Pharmaceuticals, Inc. Improved vaccines for human papilloma virus and methods for using the same
AU2017332854B2 (en) 2016-09-21 2024-11-14 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
JP6795468B2 (ja) * 2017-07-14 2020-12-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
JP7075130B2 (ja) * 2019-10-25 2022-05-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395395A (en) * 1979-05-21 1983-07-26 The United States Of America As Represented By The Department Of Health And Human Services Detection of non-A, non-B hepatitis associated antigen
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
RU2123528C1 (ru) * 1990-11-08 1998-12-20 Чирон Корпорейшн Способ получения белков hcv, пригодных для использования в вакцине или иммуноанализе, асиалогликопротеин (варианты), композиция для использования в вакцине или в иммуноанализе (варианты), способ очистки асиалогликопротеина и способ понижения содержания или элиминации hcv
PT992580E (pt) * 1993-11-04 2005-07-29 Innogenetics Nv Epitopos para celulas t humanas imunodominantes do virus da hepatite c
WO1996004385A2 (en) * 1994-07-29 1996-02-15 Innogenetics N.V. Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
DE69526973T3 (de) * 1994-10-21 2010-01-07 Innogenetics N.V. Sequenzen von hepatitis-c-virus genotype 7, und deren verwendung als vorbeugende, therapeutische und diagnostische mittel
CA2269097C (en) * 1996-11-08 2007-01-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Synthesis and purification of hepatitis c virus-like particles
CZ298268B6 (cs) * 1998-04-17 2007-08-08 Innogenetics N. V. Imunodiagnostický test používající redukující cinidla
EP1090033B2 (de) * 1998-06-24 2007-12-19 Innogenetics N.V. Hcv hüllproteine partikel : verwendung für therapeutische impfung

Also Published As

Publication number Publication date
PL345018A1 (en) 2001-11-19
EP1090033A1 (de) 2001-04-11
ES2237115T5 (es) 2008-05-16
AU765940B2 (en) 2003-10-02
DE69922958T3 (de) 2008-06-26
CN1313864A (zh) 2001-09-19
RU2247729C2 (ru) 2005-03-10
HUP0102478A3 (en) 2004-10-28
HK1037639A1 (en) 2002-02-15
KR20010053181A (ko) 2001-06-25
DE69922958D1 (de) 2005-02-03
NZ508797A (en) 2004-02-27
HUP0102478A2 (hu) 2001-10-28
CA2330526A1 (en) 1999-12-29
HU227275B1 (en) 2011-01-28
EP1090033B1 (de) 2004-12-29
US20060275323A1 (en) 2006-12-07
TR200003843T2 (tr) 2001-06-21
NZ528952A (en) 2004-09-24
KR100559096B1 (ko) 2006-03-15
EP1090033B2 (de) 2007-12-19
BR9911397A (pt) 2002-01-15
IL140217A (en) 2009-09-22
PL201679B1 (pl) 2009-04-30
US20030202987A1 (en) 2003-10-30
JP2002518037A (ja) 2002-06-25
ES2237115T3 (es) 2005-07-16
PT1090033E (pt) 2005-05-31
DK1090033T3 (da) 2005-04-25
EP1555270A1 (de) 2005-07-20
IL140217A0 (en) 2002-02-10
WO1999067285A1 (en) 1999-12-29
DE69922958T2 (de) 2006-03-30
US6635257B1 (en) 2003-10-21
DK1090033T4 (da) 2008-03-31
AU4615299A (en) 2000-01-10

Similar Documents

Publication Publication Date Title
DE69922958D1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
ATE404220T1 (de) Rekombinierte pockenvirus-tollwut zusammensetzung und kombinierte zusammensetzungen und deren verwendung
DE10299044I1 (de) n-Terminal chemisch modifizierte Protein-Zusammensetzungen und Methoden
EE200200709A (et) Liitvalku sisaldava kompositsiooni ning seda liitvalku ja liitpolüpeptiidi kodeeriva nukleiinhappe kasutamine
MA24638A1 (fr) Vaccin
CY1106806T1 (el) Dna και πολυπεπτιδια ανθρωπινης tslp
ATE405647T1 (de) Rekombinantes gelatin in impstoffen
AU6160201A (en) Human polypeptides causing or leading to the killing of cells including lymphoidtumor cells
AU2002220460A1 (en) The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits
WO2004085633A8 (en) A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
DK0909323T3 (da) Helicobacter pylori-bakterioferritin
DE602004027362D1 (de) Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
MXPA04005891A (es) Proteinas envolventes del virus de hepatitis c purificadas para diagnostico y uso terapeutico.
ATE237691T1 (de) Rekombinantes pockenvirus der infektiösen peritonitis der katze, dessen zusammensetzungen und methoden zur herstellung und verwendung
ATE425187T1 (de) Materialien und methoden zur behandlung von hepatitis c
DE69736779D1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
DK1423525T3 (da) Rekombinant MVA, der kan eksprimere HCV-strukturantigener
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
IL151033A0 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
DE60024977D1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
ZA896942B (en) Allelic variants of plasmodium falciparum merozoite surface antigen
ATE415419T1 (de) Inaktivierte zytokine zur immunisierung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1090033

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1090033

Country of ref document: EP

REN Ceased due to non-payment of the annual fee